ALTERITY THERAPEUTICS LIMITED Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will participate in investor meetings at the Benchmark Company Healthcare House Call Conference.The conference is taking place virtually on Thursday, 2 June 2022.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company's lead asset, ATH434, has the potential to treat various Parkinsonian disorders. Alterity also has a broad drug discovery platform generating patentable chemical compounds to intercede in disease processes. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company's web site at www.alteritytherapeutics.com.
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
January 7, 2021May 19, 2021
November 20, 2019November 20, 2019
August 1, 2019May 19, 2021
Your email address will not be published.Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
Δ
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Alterity Therapeutics Ltd. published this content on 26 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 May 2022 06:48:37 UTC.
